Sartorius Stedim Biotech opened a new bioanalytical and biosafety testing facility in Boston that will focus on helping U.S. companies accelerate development of biosimilars and move other bioproducts quickly into clinical trials. 

According to Reinhardt Vogt, member of SSB’s Executive Committee, the new lab is designed to accommodate the demand for the company’s BioOutsource brand specialized assay platforms in North America and to facilitate the ongoing expansion of this service offering.

Previous articleGenetic Mutations Found That Distinguish Aggressive Meningiomas from Benign Forms
Next articleBMS Acquires Exclusive Rights to Nitto Denko NASH Candidate